Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma

Ioana Agache, Jessica Beltran, Cezmi Akdis, Mubeccel Akdis, Carlos Canelo-Aybar, Walter Canonica, Thomas Casale, Tomas Chivato, Jonathan Corren, Stefano Del Giacco, Thomas Eiwegger, Davide Firinu, James E. Gern, Eckard Hamelmann, Nicola Hanania, Mika Mäkelä, Irene Hernández Martín, Parameswaran Nair, Liam O’Mahony, Nikolaos G. PapadopoulosAlberto Papi, Hae-Sim Park, Luis Pérez de Llano, Margarita Posso, Claudio Rocha, Santiago Quirce, Joaquin Sastre, Mohamed Shamji, Yang Song, Corinna Steiner, Jurgen Schwarze, Pablo Alonso-Coello, Oscar Palomares, Marek Jutel

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalAllergy : European journal of allergy and clinical immunology
Volume75
Issue number5
Pages (from-to)1023-1042
Number of pages20
ISSN0105-4538
DOIs
Publication statusPublished - May 2020
MoE publication typeA1 Journal article-refereed

Fields of Science

  • benralizumab
  • cost-effectiveness
  • dupilumab
  • eosinophilic asthma
  • exacerbations
  • mepolizumab
  • omalizumab
  • reslizumab
  • severe asthma
  • MULTICENTER
  • QUALITY
  • BIOMARKER
  • SURROGATES
  • INFORMATION
  • GUIDELINES
  • INHALED CORTICOSTEROIDS
  • ECONOMIC EVALUATIONS
  • severe-eosinophilic-asthma
  • efficacy
  • biologicals
  • SPUTUM EOSINOPHIL
  • safety
  • DOUBLE-BLIND
  • 3111 Biomedicine
  • 3121 Internal medicine

Cite this